Literature DB >> 25620063

A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma.

Maja V Maraldo1, Michael Lundemann2, Ivan R Vogelius2, Lena Specht3.   

Abstract

INTRODUCTION: Reconstruction of radiotherapy (RT) performed decades ago is challenging, but is necessary to address dose-response questions from epidemiological data and may be relevant in re-irradiation scenarios. Here, a novel method to reconstruct extended and involved field RT for patients with Hodgkin lymphoma was used.
MATERIALS AND METHODS: For 46 model patients, 29 organs at risk (OARs) were contoured and seven treatment fields reconstructed (mantle, mediastinal, right/left neck, right/left axillary, and spleen field). Extended and involved field RT were simulated by generating RT plans by superpositions of the seven individual fields. The mean (standard deviation) of the 46 individual mean organ doses were extracted as percent of prescribed dose for each field superposition.
RESULTS: The estimated mean doses to the OARs from 17 field combinations were presented. The inter-patient variability was found to be a larger contributor to the uncertainty than the field simulation process. The inter-patient variability depended on the OAR and primarily affected the estimates for OARs located at the edge of the RT field.
CONCLUSIONS: Dose estimates for 29 OARs were reported from extended and involved field RT. These estimates could be employed when individual reconstruction is not feasible and estimated doses from past treatments are needed.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Dose estimates; Extended field; Hodgkin lymphoma; Involved field; Normal tissues

Mesh:

Year:  2015        PMID: 25620063     DOI: 10.1016/j.radonc.2015.01.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Retrospective estimation of heart and lung doses in pediatric patients treated with spinal irradiation.

Authors:  Daniel Gasic; Per Munck Af Rosenschöld; Ivan R Vogelius; Maja V Maraldo; Marianne C Aznar; Karsten Nysom; Thomas Björk-Eriksson; Søren M Bentzen; Nils Patrik Brodin
Journal:  Radiother Oncol       Date:  2018-05-30       Impact factor: 6.280

2.  Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy.

Authors:  Nicola S Russell; Inge M Krul; Anna M van Eggermond; Berthe M P Aleman; Rosie Cooke; Susanne Kuiper; Steven D Allen; Matthew G Wallis; Damien Llanas; Ibrahima Diallo; Florent de Vathaire; Susan A Smith; Michael Hauptmann; Annegien Broeks; Anthony J Swerdlow; Flora E Van Leeuwen
Journal:  Clin Transl Radiat Oncol       Date:  2017-10-24

3.  Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.

Authors:  David J Cutter; Johanna Ramroth; Patricia Diez; Andy Buckle; Georgios Ntentas; Bilyana Popova; Laura Clifton-Hadley; Peter J Hoskin; Sarah C Darby; John Radford; Tim Illidge
Journal:  J Clin Oncol       Date:  2021-08-13       Impact factor: 50.717

4.  Imaging dose and secondary cancer risk in image-guided radiotherapy of pediatric patients.

Authors:  Yvonne Dzierma; Katharina Mikulla; Patrick Richter; Katharina Bell; Patrick Melchior; Frank Nuesken; Christian Rübe
Journal:  Radiat Oncol       Date:  2018-09-05       Impact factor: 3.481

5.  Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry.

Authors:  David A Jones; Paolo Candio; Rebecca Shakir; Georgios Ntentas; Johanna Ramroth; Alastair M Gray; David J Cutter
Journal:  Blood Adv       Date:  2022-02-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.